Ninety-two patients with schizophrenia were included in a double-blind multicentre parallel-group trial comparing remoxipride and haloperidol. The mean daily dose during the last week of treatment was 316 mg (range, 150-600 mg) in the remoxipride group and 8.7 mg (range, 5-20 mg) in the haloperidol group. The study period was six weeks with at least one day of washout. Both Clinical Global Impression (CGI) rating, and Brief Psychiatric Rating Scale (BPRS) total scores declined at the end of the trial compared with pretreatment values in both groups. No significant differences were found between the remoxipride and haloperidol groups with regard to the treatment outcome. Treatment-emergent extrapyramidal symptoms were statistically more frequent and more severe during haloperidol than during remoxipride treatment. Haloperidol-treated patients reported also significantly more concentration difficulties. Severe extrapyramidal side effects in the haloperidol group and clinical ineffectiveness in the remoxipride group were the most frequent reasons for premature discontinuation of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0447.1990.tb05298.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells.
Pharmacology
October 2020
Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Background: Glioblastoma multiforme (GBM) is a common and lethal cancer of the central nervous system. This cancer is difficult to treat because most anticancer therapeutics do not readily penetrate into the brain due to the tight control at the cerebrovascular barrier. Numerous studies have suggested that dopamine D2 receptor (D2R) antagonists, such as first generation antipsychotics, may have anticancer efficacy in vivo and in vitro.
View Article and Find Full Text PDFThe dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.
J Neural Transm (Vienna)
November 2014
Department of Pharmacology, Institute of Neuroscience and Physiology, University of Gothenburg, Box 431, 405 30, Gōteborg, Sweden,
Article Synopsis
- Pridopidine and ordopidine are dopaminergic stabilizers that reduce hyperactivity caused by psychostimulants and promote behavior when activity is low, distinguishing their effects from other D2 receptor antagonists.
- Both compounds were shown to significantly increase the expression of the immediate early gene Arc in both the frontal cortex and striatum, suggesting a unique mechanism of synaptic activation compared to standard D1 and D2 compounds.
- The increase in Arc expression in the striatum also indicated a link between dopamine D2 receptor antagonism and enhanced synaptic activity, underscoring the unique neuropharmacological profile of these stabilizers.
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Behav Brain Res
November 2009
Division of Neurobiology 2, Centre de Recherche Pierre Fabre, 17 avenue Jean Moulin, 81106 Castres, France.
Typical antipsychotics such as haloperidol exert their therapeutic effects via blockade of dopamine (DA) D(2) receptors, leading to extrapyramidal symptoms (EPS) in humans and catalepsy in rodents. In contrast, atypical antipsychotics and new generation D(2)/5-HT(1A) antipsychotics have low cataleptogenic potential. However, there has been no systematic comparative study on the effects of these different classes of antipsychotics in non-human primates, a species displaying a more sophisticated repertoire of behavioural/motor activity than rats.
View Article and Find Full Text PDFCharacterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats.
Brain Res
February 2008
Department of Pharmacological Sciences, School of Pharmaceutical Science, Health Sciences University of Hokkaido, Ishikari-Tobetsu, 060-0293 Japan.
Synaptic plasticity expressed as long-term potentiation (LTP) in the hippocampal-medial prefrontal cortex (mPFC) pathway is considered to be involved in cognitive function and learning and memory processes, but its synaptic mechanism remains unknown. The present study characterized LTP in the mPFC using the atypical antipsychotic clozapine, with a focus on dopaminergic modulation. The magnitude of LTP was facilitated by pretreatment with clozapine (20 mg/kg, i.
View Article and Find Full Text PDFInhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action.
J Physiol Pharmacol
June 2006
Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.
Antipsychotic drugs are widely used to alleviate a number of psychic disorders and have been found to modulate some immune parameters, but the molecular mechanism of their action on the proliferative activity has been poorly recognized. In the present study, we investigated effects of various antipsychotics on the proliferative activity of lymphocytes stimulated by concanavalin A (Con A) and lipopolysaccharide (LPS). Chlorpromazine (3 x 10(-6)-10(-4) M) showed the most potent effect in inhibiting 3H-thymidine incorporation into C57BL/6 mouse spleen cells stimulated by Con A and LPS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!